[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mpox\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mpox":108},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,69,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100643071","validation-of-sds-edta-treated-chromatography-paper-strips-for-mpox-sampling-and-transport-in-drc-100643071",false,"NCT07634081","Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRC","Use of SDS\u002FEDTA-Treated Chromatography Strips for Sampling, Transportation and Laboratory Confirmation of Mpox Virus Infection","Inclusion Criteria:\n\n* Patients presenting with clinical signs compatible with mpox infection according to national case definition.\n* Written informed consent obtained.\n* Presence of at least two skin lesions in a similar stage of evolution suitable for paired sampling.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Presence of only one suitable lesion for sampling.\n* Lesions at markedly different stages of evolution.\n* Inability to safely obtain paired samples.","ALL",{"count":18,"type":19},150,"ESTIMATED","1 Day","OBSERVATIONAL","The objective of this prospective paired diagnostic comparison study is to evaluate the diagnostic yield and field applicability of SDS-EDTA-treated chromatography paper strips for the collection, transport, and laboratory detection of mpox virus compared with the routine swab-based sampling method under field conditions in the Democratic Republic of the Congo (DRC).\n\nThe study is conducted among patients with suspected mpox infection presenting to healthcare facilities in South Kivu, DRC. For each participant, paired samples are collected simultaneously using the standard swab method and the SDS-EDTA strip method. Samples are analyzed using locally available molecular diagnostic platforms.",[24],"Mpox","RECRUITING","2026-06-09",{"date":28,"type":29},"2026-06-11","ACTUAL",{"date":31,"type":29},"2026-05-01",{"date":33,"type":19},"2026-07-31",{"name":35,"class":36},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":37},"100600130","evaluation-of-effectiveness-and-safety-of-lc16m8-mpox-vaccine-in-the-democratic-republic-of-congo-drc-100600130","NCT07093489","Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)","Evaluation of the Effectiveness and Safety of the LC16m8 Mpox Vaccine in Individuals Aged One Year and Older in the Democratic Republic of Congo (DRC)","MPX-001","1. Vaccination:\n\n   Inclusion criteria\n   * Individuals aged 12 months and above\n   * Living in the study catchment area\n   * Written informed consent\u002Fassent (if applicable)\n\n   Exclusion criteria\n   * Prior receipt of any mpox vaccine dose\n   * Women known to be pregnant or breast feeding\n   * Individuals suffering from any spreading skin disease\n   * Immunocompromised individuals with known severe immuno-deficiency conditions (example, HIVAIDS, individuals being on chronic use of systemic steroids (\\>2 mg\u002Fkg\u002Fday or \\>20 mg\u002Fday prednisolone equivalent for periods exceeding 10 days, cytotoxic or other immunosuppressive drugs)\n   * Individuals with known underlying uncontrolled chronic diseases such as diabetes mellitus, cardiovascular disease, renal disease, hepatic disease, hematological disease, and developmental disturbance\n   * Individuals with a history of hypersensitivity caused by a component of the vaccine\n\n   Temporary exclusion criteria\n   * Individuals with objective fever (Frontal temperature ≥ 38.5°C) or axillary temperature \\> 37.5 °C\n   * Individuals suffering from acute illness within 48 hours prior to vaccination and based on investigator judgement.\n   * Receipt of any live vaccine injection within the previous 27 days (measles vaccine, rubella vaccine, mumps vaccine, varicella vaccine, BCG vaccine, yellow fever vaccine...).\n2. Cohort Event Monitoring (CEM):\n\n   Inclusion criteria\n   * Written informed consent\n   * Individual who receives single dose of LC16m8 vaccine at one of the vaccination centers participating in the study.\n   * Must be reachable by phone (must have an active phone number of his\u002Fher own or in the household) throughout study participation.\n\n   Exclusion criteria\n\n   • Individual\u002Fparent\u002Fguardian unable to comply with the study procedures\n3. Mpox surveillance (VE):\n\nGeneral Inclusion Criteria:\n\n* Patients (with any vaccination status) presenting to a sentinel surveillance health facility with clinical signs and symptoms consistent with mpox disease (probable or suspected)\n* Reside in the study area prior to testing.\n* Eligible to receive LC16m8 vaccine during the vaccination.\n* Give consent\u002Fassent (if applicable) to participate in the study.\n\nExclusion Criteria\n\n* Individuals meeting any of the following criteria are not eligible for testing and enrollment in the study:\n* Known contraindications for LC16m8 vaccine.\n* As per the Investigator's medical judgement, an individual could be excluded from the study despite meeting all the inclusion\u002Fexclusion criteria mentioned above.",true,"1 Year",{"count":49,"type":19},11990,"12 Weeks","This is a health facility-based prospective test-negative (TND) case-control study to evaluate vaccine effectiveness and active safety monitoring (cohort event monitoring), and passive surveillance for evaluation of the safety of the LC16m8 mpox vaccine in individuals aged one year and older in the DRC.\n\nThis study aims to assess the LC16m8 vaccine effectiveness and safety. The following activities will be carried out:\n\n* Community engagement\n* Enhanced health facility-based mpox disease surveillance\n* Vaccination using the LC16m8 vaccine\n* Safety monitoring following immunization\n* LC16m8 Vaccine effectiveness evaluation using a TND\n\nStudy Hypothesis: The LC16m8 vaccine, administered as pre-exposure prophylaxis, confers greater than 70% protection against symptomatic mpox disease among adults and children in the DRC.",[53,24],"Mpox (Monkeypox)",[55,24,56,57,58],"LC16m8","Effectiveness","Safety","DRC","NOT_YET_RECRUITING","2025-09-08",{"date":62,"type":29},"2025-09-15",{"date":64,"type":19},"2025-09-30",{"date":66,"type":19},"2027-12-31",{"name":68,"class":36},"International Vaccine Institute",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":46,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":37},"100584301","mpox-comprehensive-assessment-for-responsive-immunisation-in-emergency-outbreaks-100584301","NCT06887556","Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks","MPOX CARE","Inclusion Criteria:\n\n* Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements.\n* Group 1 (suspected exposure cohort) only\n\n  * Live within or adjacent to an epidemiologically identified region of Mpox transmission\n  * Close contacts of those with microbiologically confirmed Mpox\n* Group 2 (post-exposure\u002Fvaccinated cohort) only\n\n  * Previous clinically or microbiologically confirmed Mpox or confirmed previous vaccination with a smallpox\u002FMVA vaccine\n  * Fully recovered from Mpox infection\n* Group 3 (control cohort) only:\n\n  * Asymptomatic with no known exposure to Mpox\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent to take part\n* Unwilling or unable to comply with study procedures\n* History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study\n* Have a bleeding disorder deemed significant by a member of the study team\n* Pregnant or breast-feeding females\n* Group 1 (suspected exposure cohort) only\n\n  * Known history of Mpox infection\n  * Current symptoms consistent with Mpox\n  * Known exposure to Mpox in the last month\n* Group 2 (post-exposure\u002Fvaccinated cohort) only\n\n  * Participants with any ongoing symptoms of Mpox, indicating incomplete recovery.\n* Group 3 (control cohort only)\n\n  * Symptoms of Mpox\n  * Known exposure to Mpox in the last month","5 Years","80 Years",{"count":79,"type":19},650,"INTERVENTIONAL",[82],"NA","The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.",[24],"2025-03-19",{"date":87,"type":29},"2025-03-20",{"date":89,"type":29},"2025-02-05",{"date":91,"type":19},"2026-12",{"name":93,"class":36},"University of Birmingham",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":21,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":114,"locationsCount":116},"100499498","observational-prospective-cohort-study-of-mpox-infection-in-brazil-netpox-100499498","NCT05784038","Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)","Observational, Prospective, Cohort Study of Mpox Infection in Brazil - NETPOX Cohort","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years with confirmed MPOX infection.\n\n(laboratory-confirmed monkeypox infection is defined as determined by PCR, culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 4 days of randomization)\n\nExclusion Criteria:\n\n* Inability to provide informed consent;\n* Patient who, judging by the study team, does not have a condition for decentralized follow-up","18 Years",{"count":103,"type":19},80,"10 Months","The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.",[107,108],"Monkeypox","MPOX","2024-07-16",{"date":111,"type":29},"2024-07-17",{"date":109,"type":29},{"date":91,"type":19},{"name":115,"class":36},"Hospital Israelita Albert Einstein",3]